Green Plains Partners (NASDAQ:GPP) reported quarterly earnings of $0.44 per share. This is unchanged from the same period last year.
Cellectar Biosciences Receives European Medicines Agency Priority Medicines Designation For Iopofosine For Waldenstrom’s Macroglobulinemia
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that